

Variant: *NM\_000251.3(MSH2):c.1748A>G (p.Asn583Ser)*

Version: 1.0

CA019161 [↗](#)

41645 (ClinVar) [↗](#)

**Gene:** MSH2 ([HGNC:4436](#))

**Condition:** Lynch syndrome ([MONDO:0005835](#))

**Inheritance Mode:** Autosomal dominant inheritance

**UID:** 3caeeba8-927f-4038-995e-ba520590df07

**Approved on:** 2024-09-19

**Published on:** 2024-10-11

### *HGVS expressions*

#### **NM\_000251.3:c.1748A>G**

NM\_000251.3(MSH2):c.1748A>G (p.Asn583Ser)

NC\_000002.12:g.47471051A>G

CM000664.2:g.47471051A>G

NC\_000002.11:g.47698190A>G

CM000664.1:g.47698190A>G

NC\_000002.10:g.47551694A>G

NG\_007110.2:g.72928A>G

ENST00000644900.2:c.1748A>G

ENST00000233146.7:c.1748A>G

ENST00000543555.6:c.1550A>G

ENST00000644092.1:c.\*48A>G

ENST00000645339.1:c.1748A>G

ENST00000645506.1:c.1748A>G

ENST00000646415.1:c.1748A>G

ENST00000233146.6:c.1748A>G

ENST00000406134.5:c.1748A>G

ENST00000543555.5:c.1550A>G

ENST00000610696.4:c.\*144A>G

ENST00000613514.4:c.\*288A>G

ENST00000617333.3:c.\*514A>G

ENST00000617938.4:c.\*720A>G

ENST00000621359.2:c.1748A>G

NM\_000251.2:c.1748A>G

NM\_001258281.1:c.1550A>G

Likely Benign

Met criteria codes **2**

BS3 BP4

Not Met criteria codes **5**

PM2 BA1 BS2 BS1 BP5

Evidence Links **0**

Expert Panel

[InSiGHT Hereditary Colorectal Cancer/Polyposis VCEP](#) [↗](#)

Criteria Specification Information





[↗](#) **Criteria Specification:** *ClinGen InSiGHT Hereditary Colorectal Cancer/Polyposis Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for MSH2 Version 1.0.0*

Evidence submitted by expert panel










***InSiGHT Hereditary Colorectal Cancer/Polyposis VCEP***

The MSH2 c.1748A>G variant is predicted as a missense variant, p.(Asn583Ser). It has been identified at an MCAF 95% of 0.00934% in gnomAD all non-cancer v2.1.1 and Grpmax AF of 0.007999% in gnomAD v4.1. It is not predicted to affect protein function (Prior\_utah (MAPP/PP2) < than 0.11; BP4). The variant did not affect the splicing (pCAS minigene [Pascaline Gaildrat & Stephanie Baert-Desurmont]) and showed proficient function in a calibrated functional assay (PMID 33357406; BS3). The variant was found in a patient with CRC showing MSS/IHC normal (FHCRC CCFR, Insight database). According to the current guidelines, the variant is classified as likely benign. (VCEP specifications version 1)

**Met criteria codes**

<b>BS3</b>	 	No effect on splicing (pCAS minigene [Pascaline Gaildrat & Stephanie Baert-Desurmont]). Proficient function in 1 calibrated assay (loss of function score -1,96 in Jia 2021; PMID 33357406; BS3)
<b>BP4</b>	 	It is not predicted to affect protein function (Prior_utah (MAPP/PP2) = 0.000107375002699 which is < than 0.11). Moreover, it is not predicted to affect splicing (max value SpliceAI 0 and Prior_utah_splicing_de_novo = 0.02).

**Not Met criteria codes**

<b>PM2</b>		Allelic frequency in gnomAD all non-cancer v2.1.1 = 0.09336% and gnomAD v4.1 Grpmax AF = 0.007999%
<b>BA1</b>	 	Allelic frequency in gnomAD all non-cancer v2.1.1 = 0.09336%; MCAF 95% = 0.00934%.
<b>BS2</b>	 	Co-observation with pathogenic variants in MLH1: MLH1 c.1852_1854del p.(Lys618del) (CRC age <50 Marseille UMD db entry); MLH1 c.589-1G>T (CRC age 35 Wagner et al., 2003, Chao et al., 2008).
<b>BS1</b>	 	Allelic frequency in gnomAD all non-cancer v2.1.1 = 0.09336%; MCAF 95% = 0.00934%. Allelic frequency in Bridges consortium: 11/53461 controls = 0.02% (PMID 33471991).
<b>BP5</b>	 	1 patient with CRC showing MSS/IHC normal (FHCRC CCFR, Insight database)

Curation History [↗](#)

	▼	▼
--	---	---

Showing 1 to 1 of 1 rows

--

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.